Rotigotine
- Generic Name
- Rotigotine
- Brand Names
- Neupro
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25NOS
- CAS Number
- 99755-59-6
- Unique Ingredient Identifier
- 87T4T8BO2E
- Background
Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours.
...
- Indication
For use/treatment in neurologic disorders and parkinson's disease as well as moderate-to-severe primary Restless Legs Syndrome.
- Associated Conditions
- Moderate restless legs syndrome (RLS), Parkinson's Disease (PD), Severe restless legs syndrome (RLS)
- Associated Therapies
- -
Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease
- First Posted Date
- 2007-08-22
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 84
- Registration Number
- NCT00519532
An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 186
- Registration Number
- NCT00505687
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 395
- Registration Number
- NCT00501969
Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects
- Conditions
- First Posted Date
- 2007-07-09
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 341
- Registration Number
- NCT00498108
Long-term Open-label Trial in Idiopathic Restless Legs Syndrome (RLS)
- First Posted Date
- 2007-07-09
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 295
- Registration Number
- NCT00498186
Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2015-06-22
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 287
- Registration Number
- NCT00474058
The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults.
- First Posted Date
- 2007-04-24
- Last Posted Date
- 2015-06-22
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 230
- Registration Number
- NCT00464737
Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 130
- Registration Number
- NCT00292227
- Locations
- 🇿🇦
Farmovs-Parexel (Pty) Ltd, Bloemfontein, South Africa
🇿🇦Qdot, a division of Parexel International DA (Pty) Ltd., George, South Africa
A Sleep Lab Trial to Investigate the Efficacy and Safety of Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome
- Conditions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT00275236
- Locations
- 🇩🇪
Schwarz BioSciences, Monheim, Germany
An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 279
- Registration Number
- NCT00263068
- Locations
- 🇺🇸
Schwarz, RTP, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.